Loftus LT, Li HF, Gray AJ, Hirata-Fukae C, Stoica BA, Futami J, et al
Putting orforglipron in context Because obesity therapies are evolving rapidly in a market dominated by injectables since semaglutides weight-loss approval in 2021, it is helpful to view orforglipron alongside established and emerging incretin-based drugs
Laboratory studies show it stimulates fibroblasts to produce more collagen, elastin, and glycosaminoglycans
Well be breaking down their individual benefits in more depth below
Our comprehensive GLP-1 weight loss program is carefully designed for your success: Both medications are effective GLP-1 treatments for weight loss, but they work slightly differently
Stay informed on the future of metabolic health